The global crisis of bacterial resistance to antibiotics increasingly threatens human health and burdens healthcare systems. Effective treatment alternatives are diminishing. Centers for Disease Control have highlighted specific drug-resistant pathogens that present the most serious and urgent threats. Development of new effective antibiotics to address these threats has not kept pace given the challenges in identification, development, and profitable commercialization. However, recent changes in legislation and guidance (including defined clinical study endpoints, shortened NDA review times, QIDP status, improved exclusivity, and proposed pull incentives) bring hope and motivate new antibiotic development. The time to act is now.

FleurirABX is a privately held company headquartered in Raleigh, NC, formed to address this global crisis and bring significant value to patients, partners and investors by discovering, developing and marketing small molecule antibacterial drugs that fulfill unmet patient and societal needs.

Latest News and Events

The FleurirABX team presented two posters at the 2022 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting held in April 2022 in Lisbon, Portugal.
Read More >